Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus
NCT04403672 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2020-05-28
Summary
The novel Severe acute respiratory syndrome coronavirus 2 (SARS-C0V 2) originated in Wuhan, China in December 2019. As of April 15 2020, the virus has spread across 213 countries/territories with 1,914,916 cases and 123,010 deaths and a crude case fatality ratio (CFR) of 6.4%. In Bangladesh, the situation is also grave. As of May 14, 2020, there were 18,863 cases and 283 deaths.
In order to suppress COVID-19 transmission, it is important to diagnose COVID-19 patients, which would help in the process of quarantine and isolation of the patients and also in contact tracing. COVID-19 testing can identify the SARS-CoV-2 virus and includes methods that detect the presence of virus itself such as real time reverse-transcription-polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification, antigen) and those that detect antibodies produced in response to infection. Until now, RT-PCR has been known as the best approach for - detection. It would be very useful if Bangladesh had its own locally produced RT-PCR kits, provided that the kits are no less in quality than imported kits in terms of sensitivity, specificity, price etc. The present study aims to carry out the performance evaluation of RealDetect RT-PCR Kit for COVID-19 detection.
The RealDetect™ COVID-19 RT-PCR diagnostic panel is a locally produced real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal swab specimens collected from individuals who meet SARS-CoV-2 clinical criteria. The approach is based on the RT-PCR method which uses two (Nucleocapsid 1, Nucleocapsid 2) sets of gene-specific primers and corresponding fluorescent probes to detect two specific regions within the novel coronavirus (SARS-CoV-2) nucleocapsid protein Nucleocapsid gene. This RT-PCR panel detects SARS-CoV-2 Ribonucleic acid (RNA) specifically. The approach does not generate any false positives to other coronaviruses or human microflora. The kit also contains a primer-probe set which detects human housekeeping gene, ribonuclease Protein (RNase P). That is, the Ribonuclease Protein (RNase P) serves as an internal reference control to monitor sample collection, ribonucleic acid (RNA) extraction, and amplification.
This is a case control study. The study will analyze 120 samples (60 COVID-19 positive and 60 COVID-19 negative both fresh and frozen) from Institute of Epidemiology, Disease Control and Research (IEDCR). These specimens will be blinded before handing over to Institute for Developing Science \& Health Initiatives (ideSHi) for RealDetect Kit. All samples will be analyzed by Real Time PCR System. Necessary validation will also be carried out at the COVID-19 laboratory of the Dhaka Medical College Hospital and an external validation expert will be involved. The Principal Investigator (PI) will also receive the sample information regarding positive/negative status from Institute for Epidemiology, Disease Control and Research (IEDCR) and compare ideSHi and IEDCR data. Unpaired t-test, Wilcox's test, Rank test, Compare test, Mean test, Sensitivity/Specificity test, Regression analysis and Geometric mean with 95% Confidence Interval (CI) will be used to analyze the data. It needs to conduct a univariate analysis.
Conditions
- High Sensitivity and Specificity (With 95% Confidence Interval) of RealDetect™ COVID-19 RT-PCR Kit
Interventions
- DEVICE
-
performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection
IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results. A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit.
Sponsors & Collaborators
-
Bangladesh Medical Research Council (BMRC)
lead OTHER
Principal Investigators
-
Zahid Hassan, MBBS, PhD · Bangladesh University of Health Sciences
Eligibility
- Min Age
- 5 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-18
- Primary Completion
- 2020-07-24
- Completion
- 2020-07-24
Countries
- Bangladesh
Study Locations
More Related Trials
-
Predictors of COVID-19 Infection and Disease Progression
NCT04484597 ·Status: UNKNOWN
-
Capturing Infectious COVID-19 Asymptomatic Cases in Singapore
NCT04812327 ·Status: WITHDRAWN
-
POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test
NCT04981769 ·Status: UNKNOWN
-
Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive
NCT04832828 ·Status: COMPLETED
-
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
NCT04431050 ·Status: TERMINATED
-
Canine COVID-19 Detection Phase 2 and 3
NCT04948190 ·Status: UNKNOWN
-
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
NCT04441372 ·Status: UNKNOWN
-
A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai
NCT05387304 ·Status: RECRUITING
-
COVID-19 Novel Molecular Point of Care Diagnostics Evaluation
NCT06055218 ·Status: COMPLETED
-
Covid-19 Breath Test
NCT04459962 ·Status: COMPLETED ·Phase: NA
-
Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program
NCT04443803 ·Status: COMPLETED
-
MSCT Chest in Suspected COVID-19 Patients
NCT04492865 ·Status: UNKNOWN
-
Antibody Responses in Contacts of COVID-19 Patients
NCT04444310 ·Status: UNKNOWN
-
Evaluation of Molecular Point-of-care Xpert® Xpress SARS-CoV-2 Detection Implementation in Resource-limited Settings
NCT05514886 ·Status: COMPLETED
-
Assessing Performance of the Testing Done Simple Covid 19 Antigen Test
NCT05610449 ·Status: COMPLETED
-
Detection of COVID-19 Using Breath Analysis - Validation Study.
NCT05224622 ·Status: COMPLETED ·Phase: NA
-
IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study
NCT04462120 ·Status: UNKNOWN
-
COVID-19 Pathophysiology of Long Term Implications
NCT04813575 ·Status: UNKNOWN ·Phase: NA
-
Serological and PCR Testing for COVID-19
NCT04404062 ·Status: RECRUITING
-
Dynamic Evaluation of COVID-19 Diagnostic Tests
NCT04337996 ·Status: COMPLETED ·Phase: NA
-
PCOT for Outpatients With Acute Respiratory Tract Infection at Risk of Severe Disease in Primary Healthcare
NCT07159230 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Implementation of CRP Point of Care Testing in Primary Care to Improve Antibiotic Targeting in Respiratory Illness (ICAT)
NCT03855215 ·Status: COMPLETED ·Phase: NA
-
Research Title: Efficacy and Safety of Point- Of-care Procalcitonin Test to Reduce Antibiotic Exposure in VAP
NCT03982667 ·Status: COMPLETED ·Phase: NA
-
COVID-19 Infection in Patients With Chronic Pulmonary Diseases.
NCT05087199 ·Status: UNKNOWN
-
Biomarkers for Identification of COVID-19 Infection
NCT04322513 ·Status: UNKNOWN